E
Elliott M. Antman
Researcher at Brigham and Women's Hospital
Publications - 738
Citations - 187175
Elliott M. Antman is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 161, co-authored 716 publications receiving 179462 citations. Previous affiliations of Elliott M. Antman include Duke University & Katholieke Universiteit Leuven.
Papers
More filters
Journal ArticleDOI
In vivo electrophysiological effects of lidocaine in canine acute myocardial infarction.
TL;DR: The present study shows that lidocaine has different effects in infarcted and normal zones of the heart, and has local anesthetic actions which might explain its effectiveness in curtailing ventricular arrhythmias after acute myocardial infarction.
Journal ArticleDOI
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
Warren J. Cantor,Kenneth W. Mahaffey,Zhen Huang,Pranab Das,Dietrich C. Gulba,Stanislav Glezer,Richard L. Gallo,John Ducas,Marc Cohen,Elliott M. Antman,Anatoly Langer,Neal S. Kleiman,Harvey D. White,Robert J. Chisholm,Robert A. Harrington,James J. Ferguson,Robert M. Califf,Shaun G. Goodman +17 more
TL;DR: Smaller sheaths, radial access, and timely sheath removal may mitigate the bleeding risk associated with potent antithrombotic/platelet therapy and early catheterization.
Journal ArticleDOI
Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter
Elliott M. Antman,Andrew D. Beamer,Catherine Cantillon,Noreen McGowan,Lee Goldman,Peter L. Friedman +5 more
TL;DR: Oral propafenone is a useful and well tolerated drug for long-term suppression of symptomatic recurrences of atrial fibrillation/flutter despite a history of unresponsiveness to prior antiarrhythmic drug treatment.
Journal ArticleDOI
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Victor J. Dzau,Elliott M. Antman,Henry R. Black,David L. Hayes,JoAnn E. Manson,Jorge Plutzky,Jeffrey J. Popma,William G. Stevenson +7 more
TL;DR: A critical and comprehensive update of the current evidence for a cardiovascular disease (CVD) continuum based on the results of pathophysiological studies and the outcome of a broad range of clinical trials that have been performed in the past 15 years is presented.
Journal ArticleDOI
Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment?
TL;DR: The mortality benefit associated with primary percutaneous coronary intervention in ST-segment elevation myocardial infarction may be lost if door-to-balloon time is delayed by >1 hour compared with tissue plasminogen activator therapy door- to-needle time.